Founder Genomics is a research organization dedicated to advancing antibiotic therapies, with a particular focus on tuberculosis (TB). Their multidisciplinary team, comprising experts in theoretical biology, biochemistry, physics, statistics, and engineering, employs mathematical models, experimental data, and clinical insights to optimize drug treatment strategies at both individual and population levels.
Antibiotics and Drug Resistance: Investigating the mechanisms of antibiotic efficacy and resistance, especially concerning multidrug-resistant (MDR) and extensively drug-resistant (XDR) TB strains. The goal is to develop strategies that enhance the effectiveness of existing antibiotics and support the discovery of new drug candidates.
Population Biology: Exploring how bacterial populations evolve under selective pressures, such as drug treatments and host immune responses. This research aims to inform strategies to slow the spread of resistance and optimize public health outcomes.ons de conception durables
Biochemistry and Pharmacology: Studying the biochemical interactions between drugs and their bacterial targets, including drug absorption, distribution, metabolism, and elimination (ADME) processes. These insights help identify promising compounds, optimize dosing strategies, and reduce off-target effects.